

# SAFETY AND EFFECTIVENESS OF TRASTUZUMAB EMTANSIN IN LOCALLY ADVANCED OR METASTATIC HER 2 POSITIVE BREAST CANCER

M. MEJIAS TRUEBA<sup>1</sup>, R. JIMÉNEZ GALÁN<sup>1</sup>, M. MUÑOZ BURGOS<sup>1</sup>, A.B. GUISADO GIL<sup>1</sup>, M.D. VEGA COCA<sup>1</sup>,  
L. ABDEL KADER MARTIN<sup>1</sup>, S. FLORES MORENO<sup>1</sup>.  
<sup>1</sup>Hospital Universitario Virgen del Rocío. Seville. Spain.

## OBJECTIVE:


To evaluate the effectiveness and safety of TDM-1 in patients with advanced/metastatic HER2-positive breast cancer.

## MATERIAL AND METHODS:


- **Design:** observational retrospective study.
- **Population:** patients that received treatment with TDM-1 in unresectable or metastatic breast cancer who have previously received Trastuzumab and taxane separately or in combination, from January-2015 to June-2018.
- **Treatment:** TDM-1 was administered intravenously (3.6 mg/kg) every 3-week cycle.
- **Variables collected:** gender, age, hormone receptor expression (HR), previous lines, progression and death date, adverse events (AD), treatment discontinuation and dose reductions.
- Progression free survival (PFS) and Overall survival (OS) were measured from the time of beginning treatment with TDM-1 to the date of first progression or death, respectively. PFS and OS were calculated by Kaplan-Meier analysis.

## RESULTS:

- 40 patients: women with a mean age of 55 years (SD= ±13.7).
- 80% RH+.
- The median number of previous chemotherapy lines was 2 (range 1-6).



- Previous HER2-targeted therapies included:



- Mean follow-up was 15 months.
- Median PFS was 7 months (95% CI 4.3-9.7).
- No statistically significant differences were found in PFS according to HR status, age >65 years, number of previous lines or anti-HER2 therapy previously administered.
- Median OS was not reached, the 12-month OS was 73%.
- AD occurred in 82.5% of patients
  - 15% dose reduction
  - 17.5% discontinued treatment

Adverse events	%
Anemia	44
Hepatotoxicity	42,5
Asthenia	27,5
Thrombocytopenia	17,5
Peripheral neuropathy	15
Arthralgia	12,5

## CONCLUSION:

Our results show lower median PFS and 12-month OS than those from randomized trials. Most patients presented AD. Toxicity profile was similar to previously described in clinical trials.

